
The Colorectal Cancer (CRC) therapeutics market in the four Asia-Pacific (APAC) countries of India, Australia, China and Japan was worth $1.9 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% to $2.9 billion by 2020. Japan had the largest market in 2013, with a value of $1.2 billion, or a 65% share of the combined market of the four countries. It was followed by China, with $491m, or 26%; Australia, with $117m, or 6.2%; and India, which had the lowest market share and value, with 2.7% and $52m, respectively, but is expected to witness the fastest growth over the forecast period, with a CAGR of 11%. The respective CAGRs of China, Australia, and Japan during the forecast period are estimated to be 9%, 7.5%, and 5%.